Radiation and immunotherapy: Emerging mechanisms of synergy

Keyphrases

• Radiation Therapy 100%
• Response to Immunotherapy 75%
• Clinical Trials 50%
• Programmed Death-ligand 1 (PD-L1) 50%
• Stereotactic Body Radiotherapy 50%
• Systemic Response 50%
• Tumor 25%
• Costimulatory Molecules 25%
• Lung Cancer 25%
• Early Disease 25%
• Microenvironment 25%
• Short Course 25%
• Cancer Targeting 25%
• Metastatic Disease 25%
• Radiation Dose 25%
• Lung Cancer Treatment 25%
• Antigen Presentation 25%
• Cytotoxic T-lymphocyte antigen-4 (CTLA-4) 25%
• Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) 25%
• PD-L1 Expression 25%
• Immunotherapy Agents 25%
• Integral Component 25%
• Ongoing Clinical Trials 25%
• Tumor Control 25%
• Dose Timing 25%
• T Cell Recruitment 25%
• Lymphocyte Infiltration 25%
• Stage III Non-small Cell Lung Cancer 25%
• Early-stage Lung Cancer 25%
• Stromal Lymphocytes 25%
• Definitive Chemoradiation 25%

Medicine and Dentistry

• Immunotherapy 100%
• Radiation Therapy 40%
• Clinical Trial 30%
• Programmed Death-Ligand 1 30%
• Non Small Cell Lung Cancer 30%
• Stereotactic Body Radiation Therapy 20%
• Disease 10%
• Neoplasm 10%
• Lung Cancer 10%
• T Cell 10%
• Metastatic Carcinoma 10%
• Cancer Immunotherapy 10%
• Chemoradiotherapy 10%
• Antigen Presentation 10%
• Treatment of Lung Cancer 10%
• CTLA-4 10%
• Lymphocytic Infiltration 10%
• Stromal Tumor 10%